<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02293824</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00058253</org_study_id>
    <nct_id>NCT02293824</nct_id>
  </id_info>
  <brief_title>Effect of Feedings on Caffeine in Premature Infants</brief_title>
  <official_title>Effect of Feedings on Caffeine Pharmacokinetics and Metabolism in Premature Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Almost all infants born &lt;29 weeks gestational age develop apnea of prematurity and are
      treated with caffeine. Type of diet and disease states may be significant contributors of
      variability in caffeine metabolism and pharmacokinetics (PK) in this population. This
      prospective, observational, open-label, opportunistic PK study will compare the population PK
      of caffeine between infants fed formula and infants fed exclusively breast milk; compare the
      activities of caffeine metabolizing enzymes between infants fed formula and infants fed
      exclusively breast milk; and determine the effect of hypoxia, hypotension, and infection on
      caffeine PK and metabolism in premature infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will use a consecutive patient sampling approach. All eligible participants
      admitted at each site will be approached. Caffeine and feedings will be administered per
      standard of care. Manipulations of caffeine dosing or feeding regimens will not be a part of
      this protocol. To minimize the amount of blood sampling, the investigators will use a sparse
      sampling methodology. Urine will be collected for analysis of caffeine and caffeine
      metabolite concentrations. Caffeine pharmacokinetics will be described by population
      pharmacokinetic analysis. Urinary concentrations of caffeine and its metabolites will be used
      to calculate metabolic ratios as markers of enzyme activity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">June 30, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clearance (CL) of caffeine at steady state</measure>
    <time_frame>Study days 0, 15, 30, 45, and 60.</time_frame>
    <description>Using population pharmacokinetic analyses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (V) of caffeine at steady state</measure>
    <time_frame>Study days 0, 15, 30, 45, and 60</time_frame>
    <description>Using population pharmacokinetic analyses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caffeine metabolizing enzyme activity using urinary metabolic ratios</measure>
    <time_frame>Study days 0, 15, 30, 45, and 60</time_frame>
    <description>Activity levels of CYP1A2, xanthine oxidase, and N-acetyltransferase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold change in caffeine clearance due to hypoxia, hypotension, and infections</measure>
    <time_frame>Study days 0, 15, 30, 45, and 60</time_frame>
    <description>Effect of hypoxia, hypotension, and infections on caffeine clearance</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Apnea of Prematurity</condition>
  <condition>Premature Newborn</condition>
  <condition>Caffeine</condition>
  <arm_group>
    <arm_group_label>Premature infants</arm_group_label>
    <description>Premature infants &lt;29 weeks birth gestational age receiving caffeine per standard of care for the prevention or treatment of apnea of prematurity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine</intervention_name>
    <description>Given per standard of care.</description>
    <arm_group_label>Premature infants</arm_group_label>
    <other_name>Caffeine Citrate</other_name>
    <other_name>Cafcit</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Premature infants given caffeine for the prevention or treatment of apnea of prematurity.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent from parent(s) or legal guardian(s)

          -  &lt;29 weeks birth gestational age

          -  Postnatal age â‰¤15 days

          -  Receiving caffeine (intravenous or oral) per standard of care for prevention or
             treatment of apnea of prematurity

        Exclusion Criteria:

          -  Known major congenital or chromosomal anomaly
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>15 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip B Smith, MD, MPH, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Carolina Children's Hospital</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fbcd234e-57e1-4da2-a96c-e3f7b7cf6ec0</url>
    <description>Bedford Laboratories. CAFCIT (caffeine citrate) injection, CAFCIT (caffeine citrate) solution. 2013.</description>
  </link>
  <reference>
    <citation>Zhao J, Gonzalez F, Mu D. Apnea of prematurity: from cause to treatment. Eur J Pediatr. 2011 Sep;170(9):1097-105. doi: 10.1007/s00431-011-1409-6. Epub 2011 Feb 8. Review.</citation>
    <PMID>21301866</PMID>
  </reference>
  <reference>
    <citation>Di Fiore JM, Bloom JN, Orge F, Schutt A, Schluchter M, Cheruvu VK, Walsh M, Finer N, Martin RJ. A higher incidence of intermittent hypoxemic episodes is associated with severe retinopathy of prematurity. J Pediatr. 2010 Jul;157(1):69-73. doi: 10.1016/j.jpeds.2010.01.046. Epub 2010 Mar 20.</citation>
    <PMID>20304417</PMID>
  </reference>
  <reference>
    <citation>Janvier A, Khairy M, Kokkotis A, Cormier C, Messmer D, Barrington KJ. Apnea is associated with neurodevelopmental impairment in very low birth weight infants. J Perinatol. 2004 Dec;24(12):763-8.</citation>
    <PMID>15329741</PMID>
  </reference>
  <reference>
    <citation>Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics. 2006 Jun;117(6):1979-87.</citation>
    <PMID>16740839</PMID>
  </reference>
  <reference>
    <citation>Gal P. Caffeine Therapeutic Drug Monitoring Is Necessary and Cost-effective. J Pediatr Pharmacol Ther. 2007 Oct;12(4):212-5. doi: 10.5863/1551-6776-12.4.212.</citation>
    <PMID>23055855</PMID>
  </reference>
  <reference>
    <citation>Blake MJ, Abdel-Rahman SM, Pearce RE, Leeder JS, Kearns GL. Effect of diet on the development of drug metabolism by cytochrome P-450 enzymes in healthy infants. Pediatr Res. 2006 Dec;60(6):717-23. Epub 2006 Oct 25.</citation>
    <PMID>17065585</PMID>
  </reference>
  <reference>
    <citation>Le Guennec JC, Billon B. Delay in caffeine elimination in breast-fed infants. Pediatrics. 1987 Feb;79(2):264-8.</citation>
    <PMID>3808800</PMID>
  </reference>
  <reference>
    <citation>Xu H, Rajesan R, Harper P, Kim RB, Lonnerdal B, Yang M, Uematsu S, Hutson J, Watson-MacDonell J, Ito S. Induction of cytochrome P450 1A by cow milk-based formula: a comparative study between human milk and formula. Br J Pharmacol. 2005 Sep;146(2):296-305.</citation>
    <PMID>15997229</PMID>
  </reference>
  <reference>
    <citation>Supnet MC, David-Cu R, Walther FJ. Plasma xanthine oxidase activity and lipid hydroperoxide levels in preterm infants. Pediatr Res. 1994 Sep;36(3):283-7.</citation>
    <PMID>7808822</PMID>
  </reference>
  <reference>
    <citation>Hassoun PM, Yu FS, Cote CG, Zulueta JJ, Sawhney R, Skinner KA, Skinner HB, Parks DA, Lanzillo JJ. Upregulation of xanthine oxidase by lipopolysaccharide, interleukin-1, and hypoxia. Role in acute lung injury. Am J Respir Crit Care Med. 1998 Jul;158(1):299-305.</citation>
    <PMID>9655743</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2014</study_first_submitted>
  <study_first_submitted_qc>November 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2014</study_first_posted>
  <last_update_submitted>September 11, 2017</last_update_submitted>
  <last_update_submitted_qc>September 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infant, Premature</keyword>
  <keyword>Caffeine</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Caffeine citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Will consider on a case-by-case basis (de-identified data only)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

